States, Counties and Cities across America are uniting in a Cleveland, Ohio Multi-District Litigation (MDL) against Purdue Pharma L.P., and other manufacturers and distributors of opioids in the United States. The State of Alabama, under the leadership of Attorney General Steve Marshall, has filed suit in an effort to recoup the State’s losses.
“Prince, Glover & Hayes is ready to get to work in representing the state’s interests in this lawsuit. Alabamians are struggling with a pernicious, ever expanding epidemic of opioid addiction and abuse and the wrongdoers must be held accountable. The firm is deeply honored to have been selected by Attorney General Marshall,” says Prince, Glover & Hayes partner Josh Hayes, who has been appointed as a Deputy Attorney General. Hayes, along with his partners Bob Prince and Matt Glover will be working on this important case for the firm.
Purdue Pharma released OxyContin in 1996, and marketed the drug as a product “to start with and to stay with.” While OxyContin has reportedly generated thirty-five billion dollars for Purdue Pharma, the deceptive marketing focused on doctors and pharmacies, highly addictive nature of OxyContin, and other factors have crowned OxyContin as one of the deadliest, costliest, and widespread addiction epidemics in recent history. Sourced via “The Family That Built An Empire of Pain,” authored by Patrick Keefe , published by the New Yorker magazine on October 30th, 2017.
The complaint alleges Purdue’s marketing of these drugs contributed to the creation of the opioid epidemic, an Alabama public health and safety crisis.
Economic damages resulting from the opioid epidemic include costs for providing medical care, therapeutic care and treatments for patients suffering from opioid-related addiction or disease, including overdoses and deaths; costs for providing counseling and rehabilitation services; costs for treating infants born with opioid-related medical conditions; public safety and law enforcement expenses; and care for children whose parents suffer from opioid-related disability or incapacitation.
Purdue manufactures, markets, and sells prescription opioid pain medications, including the brand name drugs OxyContin, MS Contin, Dilaudid/Dilaudid HP, Butrans, Hysingla ER, and Targiniq ER, as well as generic opioids. OxyContin constitutes roughly 30 percent of the entire market for analgesic drugs (painkillers). Purdue’s drugs compose a majority of the extended release market, for use with chronic non-cancer pain patients, which is the most dangerous method of use. Prescription opioids constitute the largest component of the opioid epidemic, both in quantity and damage caused.
The complaint is filed in the U.S. District Court for the Middle District of Alabama Northern Division, case number 2:18-CV-00089. In addition to AG Marshall and the private counsel outlined above, the state is represented by Corey L. Maze, Special Deputy Attorney General; Winfield J. Sinclair, Assistant Attorney General; and Michael G. Dean, Assistant Attorney General.